Suchergebnisse - "Rouhani, Sherin J."

PubPharm (20)

1

Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses

enthalten in: Immunological reviews | 2023

von Blum, S. | Rouhani, S. | Sullivan, R.

2

Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics Tools

enthalten in: Biopreservation and biobanking | 2023

von Higgs, E. | Flood, B. | Pyzer, A. | +3

3

STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer

enthalten in: JCO precision oncology | 2023

von Katipally, R. | Spurr, L. | Gutiontov, S. | +19

4

Lymphatic coagulation and neutrophil extracellular traps in lung-draining lymph nodes of COVID-19 decedents

enthalten in: Blood advances | 2022

von MacDonald, M. | Weathered, R. | Stewart, E. | +17

5

Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity

enthalten in: Science advances | 2022

von Briquez, P. | Rouhani, S. | Yu, J. | +10

UpdateOf: medRxiv. 2021 Nov 02;:. - PMID 34751272

6

Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines

enthalten in: Cancer immunology research | 2022

von Reschke, R. | Shapiro, J. | Yu, J. | +4

7

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

enthalten in: Scientific reports | 2021

von Gutiontov, S. | Turchan, W. | Spurr, L. | +18

8

Sensitive detection and quantification of SARS-CoV-2 in saliva

enthalten in: Scientific reports | 2021

von Abasiyanik, M. | Flood, B. | Lin, J. | +24

UpdateOf: medRxiv. 2020 Dec 07;:. - PMID 33330880

9

Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy

enthalten in: Cancers | 2021

von Yun, N. | Rouhani, S. | Bestvina, C. | +7

10

COVIDOSE : A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia

enthalten in: Clinical pharmacology and therapeutics | 2021

von Strohbehn, G. | Heiss, B. | Rouhani, S. | +20

UpdateOf: medRxiv. 2020 Jul 26;:. - PMID 32743594